Welcome to our dedicated page for Twist Bioscience SEC filings (Ticker: TWST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Twist Bioscience Corporation filings document formal disclosures for a synthetic biology company with a silicon-based DNA synthesis platform. Form 8-K reports furnish quarterly and annual financial results, preliminary revenue information and business highlights tied to products and services such as synthetic DNA, NGS workflow tools and antibody discovery solutions.
The filing record also covers unregistered common stock issuances connected to licensing and technology-transfer arrangements, annual meeting voting results, director elections, auditor ratification, executive compensation votes, board appointments, committee service and director compensation. These disclosures address governance, capital structure and material events for TWST common stock.
TWST affiliate submitted a Form 144 notice that lists 500 shares of Common Stock proposed for sale. The filing shows these shares relate to a Restricted Stock Vesting event dated 02/07/2024. The filing also records prior sales by Melissa Starovasnik of 1,000 shares on 04/01/2026 for $51,000 and 500 shares on 04/27/2026 for $30,915.
TWST: Rule 144 notice of proposed sales and recent dispositions. The filing lists 1,399 shares identified under a restricted stock vesting entry dated 05/20/2026 and records multiple sales by Paula Green during February–May 2026 (1,465; 935; 297; 1,116 shares) with dollar proceeds shown alongside each trade. The submission describes the securities as Common shares and the broker on record as Fidelity Brokerage Services LLC.
Adam Laponis submitted a Form 144 notice reporting proposed sales of Common shares of TWST. The filing lists multiple sales in the past three months: 2,085 shares ($97,389.93), 2,597 shares ($129,561.48), 3,000 shares ($165,000.00), and 4,000 shares ($240,000.00). The filing also notes a restricted stock vesting event dated 05/20/2026.
Twist Bioscience Corp filed a Form 144 notice to sell 6,888 shares of Common Stock related to restricted stock vesting on 05/20/2026. The filing also lists multiple secondary transactions by Emily M. Leproust within the prior three months, including sales of 7,205 shares on 02/23/2026 and 8,061 shares on 04/22/2026.
The filing is a routine insider notice of proposed resale under securities rules and records recent dispositions by a reporting person; it does not state proceeds recipients beyond the selling person or additional conditions.
Dennis H. Cho reported a proposed resale of 1,642 shares of Common Stock on Form 144. The filing lists prior dispositions in the past three months: 844 shares on 02/23/2026 ($39,423.07), 425 shares on 03/06/2026 ($19,731.14), 354 shares on 03/20/2026 ($15,500.39), and 1,962 shares on 05/04/2026 ($112,125.95).
Twist Bioscience insider files a proposed sale of common stock. The filing lists 688 shares proposed for sale with Fidelity Brokerage Services LLC as broker and an execution date noted as 05/21/2026. The filing also discloses four prior open-market dispositions by Robert F. Werner totaling 6,064 shares across 02/23/2026, 03/06/2026, 05/04/2026, and 05/08/2026.
TWST filing: proposed resale of Common Stock following restricted stock vesting. The filing lists 4,160 shares of Common Stock to be sold in connection with a Restricted Stock Vesting event dated 05/20/2026. The filing also reports recent sales by Patrick Finn of 4,294, 2,321 and 2,844 shares on 02/23/2026, 04/23/2026 and 05/04/2026, respectively.
Twist Bioscience Corp director Jan Johannessen reported an option exercise and related share sale. Johannessen exercised employee stock options for 12,000 shares of common stock at $14.00 per share, increasing his holdings to 29,754 shares. On the same day, he completed an open-market sale of 12,000 common shares at an average price of $56.12 per share, leaving him with 17,754 shares held directly after the transactions. The options exercised had vested in stages over several years, subject to his continuous service.
Twist Bioscience Corp Chief Accounting Officer Robert F. Werner reported an open-market sale of Common Stock. He sold 4,961 shares on May 8, 2026 at a price of $56.881 per share. After this transaction, he directly holds 49,674 shares of Twist Bioscience Common Stock.